echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > NICE: European mantle cell lymphoma patients will fully benefit from CAR-T cell therapy!

    NICE: European mantle cell lymphoma patients will fully benefit from CAR-T cell therapy!

    • Last Update: 2021-03-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Mantle cell lymphoma is a rare and often highly invasive non-Hodgkin lymphoma (NHL).


    Lymphoma

    Tecartus is a CAR-T cell therapy targeting CD19 .


    Tecartus is a CAR-T cell therapy targeting CD19 .


    The new NICE guidelines point out that this treatment can be considered for patients with relapsed and refractory mantle cell lymphoma.


    NICE has reached an agreement with manufacturer Kite through the Cancer Drug Fund (CDF) to collect more data while patients receive treatment.


    fund

    A study conducted by NICE's independent evaluation committee on Tecartus showed that patients treated with CAR-T cell therapy may live longer and have longer intervals between disease recurrences.


     

    Original source:

    Original source:

    https://target="_blank" rel="noopener">https:// style="vertical-align: inherit;"> https:// leave a message here

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.